Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Disease/Condition
- Pancreatic Cancer
- Drug/Device/Intervention
- Irinotecan liposome II combination therapy regimen
- Study type
- Observational
- Intervention type
- drug
- Primary sponsor
- Peking Union Medical College Hospital
- Location
- Beijing, China
- Phase
- N/A
- Start date
- Apr 19, 2024
- End date
- Apr 19, 2027
- Enrollment
- 3000 participants
rwTEAE
This study is a multi-center observational study.The start time for data collection is May 1,
 2024. Patients' baseline and treatment data will be collected under informed concent. The
 purpose of this case registry study was to evaluate the safety and efficacy of irinotecan
 hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer
 in the real world by collecting, understanding, and analyzing the etiology, clinical
 features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic
 cancer patients receiving this regimen.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06375473
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06375473 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 3000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.